Elizabeth Smyth, Chan Y. Cheah, John F. Seymour.
Cancer Treatment Reviews
January 04, 2023
The indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of lymphoproliferative disorders characterized by slow growth kinetics and a relapsing/remitting course. Management has, until recently, been uniform across all indolent B-NHL subtypes. Improving insight into pathophysiological and molecular features of each disease has led to development of several targeted therapies. Consequently, each subtype must now be considered an individual entity. In this review, we consider the three commonest indolent B-NHLs: follicular lymphoma, marginal zone lymphoma and Waldenstrom’s macroglobulinemia and review in detail the data on approved and emerging targeted therapeutic agents for each B-NHL subtype.